| 4.25 0.02 (0.47%) | 09-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.41 | 1-year : | 17.23 |
| Resists | First : | 10.63 | Second : | 14.76 |
| Pivot price | 4.57  |
|||
| Supports | First : | 3.95 | Second : | 3.28 |
| MAs | MA(5) : | 4.32 |
MA(20) : | 4.79 |
| MA(100) : | 11.5 |
MA(250) : | 13.27 |
|
| MACD | MACD : | -1.7 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 9.3 |
D(3) : | 7.5 |
| RSI | RSI(14): 28.5 |
|||
| 52-week | High : | 19.11 | Low : | 3.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EYPT ] has closed above bottom band by 16.8%. Bollinger Bands are 75.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.35 - 4.37 | 4.37 - 4.4 |
| Low: | 4.09 - 4.13 | 4.13 - 4.16 |
| Close: | 4.19 - 4.25 | 4.25 - 4.3 |
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Fri, 04 Sep 2026
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
Wed, 26 Aug 2026
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky - PR Newswire
Fri, 21 Aug 2026
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) - Business Wire
Wed, 19 Aug 2026
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs. Eylea May Be Overblown (EYPT) - Seeking Alpha
Tue, 18 Aug 2026
EYPT Stock Plunges As LUGANO Miss Resets High-Risk Catalyst Trade - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 84 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 111.4 (%) |
| Shares Short | 18,430 (K) |
| Shares Short P.Month | 16,430 (K) |
| EPS | -3.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | -450.7 % |
| Return on Assets (ttm) | -74.9 % |
| Return on Equity (ttm) | -148.7 % |
| Qtrly Rev. Growth | 161.6 % |
| Gross Profit (p.s.) | -3.08 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -3.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -267 (M) |
| Levered Free Cash Flow | -155 (M) |
| PE Ratio | -1.14 |
| PEG Ratio | 0 |
| Price to Book value | 10.62 |
| Price to Sales | 127.71 |
| Price to Cash Flow | -1.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|